President Donald Trump plans to impose 100% tariffs on imported patented pharmaceuticals and their active ingredients, according to a draft order, as part of his "Most Favored Nation" initiative to lower drug prices by encouraging direct consumer sales.
Tariff Details
- The tariffs would apply specifically to drugs with patents and their active ingredients.
- A 100% levy is specified in the draft order, which is not final and may change.
- It remains unclear whether any medication types will be exempt from the tariffs.
Pathways to Avoid or Reduce Tariffs
Drugmakers can avoid or lessen tariffs by:
- Negotiating deals with the administration to sell drugs directly to consumers under the "Most Favored Nation" pricing program.
- Moving production to the United States, which would reduce the tariff rate to 20% for four years, though it would revert to 100% in 2030.
Context and Legal Background
- This action follows the Supreme Court's February ruling that some of Trump's previous tariffs were unconstitutional.
- Trump aims to rebuild his trade strategy using new regulatory avenues, despite GOP concerns about increased costs for Americans.
- The "Most Favored Nation" initiative has already secured agreements with over a dozen companies for direct drug sales, though it covers a limited selection, often with cheaper generic alternatives.
Current Status
- The White House has not responded to requests for comment.
- Bloomberg first reported the planned tariffs, with an announcement expected as early as Thursday afternoon.
- The draft order could be modified before final implementation.